Literature DB >> 22114771

The pharmacokinetics and pharmacodynamics of cisatracurium in critically ill patients with severe sepsis.

Xin Liu1, Peter S Kruger, Michael Weiss, Michael S Roberts.   

Abstract

AIM: To characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of cisatracurium in critically ill patients with severe sepsis.
METHODS: Blood samples were collected before and over 8 h after a single bolus dose of cisatracurium 0.1 mg kg(-1) . Neuromuscular block was assessed by accelerometric peripheral nerve stimulation (TOF Watch). Plasma concentration and neuromuscular block data were fitted using population analysis.
RESULTS: Steady-state volume of distribution was determined to be 111 ± 71 ml kg(-1) and plasma clearance was 5.2 ± 1.8 ml min(-1) kg(-1) in these patients with greater inter-patient variability compared with other populations. The time to maximum block (8.3 ± 2.9 min) and delay time of transferring from central to effect compartment (17.2 min) was much longer, while the maximum block (95.0 ± 6.3%) was less compared with those in other patient populations. The effect compartment concentration resulting in 50% of maximum effect (128 ± 58 ng ml(-1)) was larger than previously described.
CONCLUSIONS: This study suggests that standard dosing of cisatracurium in patients with severe sepsis results in a slower patient response with a reduced effect. Use of a larger dose may overcome this reduced delayed response.
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22114771      PMCID: PMC3403201          DOI: 10.1111/j.1365-2125.2011.04149.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  27 in total

1.  TOF monitoring is required to achieve effective transient neuromuscular blockade in ICU patients.

Authors:  F Lagneau; B Plaud; M Feller; J Marty
Journal:  Can J Anaesth       Date:  2001-03       Impact factor: 5.063

Review 2.  Up-and-down regulation of skeletal muscle acetylcholine receptors. Effects on neuromuscular blockers.

Authors:  J A Martyn; D A White; G A Gronert; R S Jaffe; J M Ward
Journal:  Anesthesiology       Date:  1992-05       Impact factor: 7.892

Review 3.  American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.

Authors: 
Journal:  Crit Care Med       Date:  1992-06       Impact factor: 7.598

4.  APACHE II: a severity of disease classification system.

Authors:  W A Knaus; E A Draper; D P Wagner; J E Zimmerman
Journal:  Crit Care Med       Date:  1985-10       Impact factor: 7.598

5.  Persistent paralysis in critically ill patients after long-term administration of vecuronium.

Authors:  V Segredo; J E Caldwell; M A Matthay; M L Sharma; L D Gruenke; R D Miller
Journal:  N Engl J Med       Date:  1992-08-20       Impact factor: 91.245

6.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

7.  Altered aminoglycoside pharmacokinetics in the critically ill.

Authors:  M J Beckhouse; I M Whyte; P L Byth; J C Napier; A J Smith
Journal:  Anaesth Intensive Care       Date:  1988-11       Impact factor: 1.669

8.  Aminoglycoside volume of distribution and illness severity in critically ill septic patients.

Authors:  P E Marik
Journal:  Anaesth Intensive Care       Date:  1993-04       Impact factor: 1.669

9.  Systemic inflammation leads to resistance to atracurium without increasing membrane expression of acetylcholine receptors.

Authors:  Heidrun Fink; Peter Luppa; Barbara Mayer; Hilkea Rosenbrock; Jochen Metzger; J A Jeevendra Martyn; Manfred Blobner
Journal:  Anesthesiology       Date:  2003-01       Impact factor: 7.892

10.  Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure.

Authors:  N B Eastwood; A H Boyd; C J Parker; J M Hunter
Journal:  Br J Anaesth       Date:  1995-10       Impact factor: 9.166

View more
  3 in total

1.  Altered pharmacodynamics and pharmacokinetics of cisatracurium in patients with severe mitral valve regurgitation during anaesthetic induction period.

Authors:  Jiayi Liu; Chunying Lu; Qirong Zou; Sheng Wang; Xuemei Peng
Journal:  Br J Clin Pharmacol       Date:  2016-10-16       Impact factor: 4.335

2.  Abnormal cisatracurium pharmacodynamics and pharmacokinetics among patients with severe aortic regurgitation during anesthetic induction.

Authors:  Xiaocong Huang; Lei Chen; Yujing Cai; Jinfeng Wei; Lina Lin; Jie Sun; Xuemei Peng; Sheng Wang
Journal:  BMC Anesthesiol       Date:  2020-01-22       Impact factor: 2.217

3.  Pharmacokinetics and pharmacodynamics studies of a loading dose of cisatracurium in critically ill patients with respiratory failure.

Authors:  Panadda Panusitthikorn; Chuthamanee Suthisisang; Viratch Tangsujaritvijit; Wichit Nosoongnoen; Pitchaya Dilokpattanamongkol
Journal:  BMC Anesthesiol       Date:  2022-01-22       Impact factor: 2.217

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.